Research Article

Granulocyte Colony Stimulating Factor Ameliorates Hepatic Steatosis Associated with Improvement of Autophagy in Diabetic Rats

Hyun-Woo Joo,1 Yi-Sun Song,1 In-Hwa Park,1 Guang-Yin Shen,2,3 Jin-Hee Seong,1 Na-Kyoung Shin,1 A-Hyeon Lee,1 Hyuck Kim,4 and Kyung-Soo Kim*1,2

1Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul, Republic of Korea
2Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Republic of Korea
3Department of Cardiology, Jilin University Jilin Central Hospital, Jilin, China
4Department of Thoracic and Cardiovascular Surgery, Hanyang University College of Medicine, Seoul, Republic of Korea

Correspondence should be addressed to Kyung-Soo Kim; kskim@hanyang.ac.kr

Received 30 December 2019; Revised 4 June 2020; Accepted 11 June 2020; Published 25 July 2020

Academic Editor: Alessandro Granito

Copyright © 2020 Hyun-Woo Joo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. We previously reported that the granulocyte colony stimulating factor (G-CSF) ameliorated hepatic steatosis with the enhancement of β-oxidation-related gene expression. However, the mechanisms underlying this process remain unclear. This study aimed to determine whether the improvement of hepatic steatosis by G-CSF was associated with autophagy in a rat model of diabetes. Methods. Eight rats were fed a standard diet, and 16 rats were fed high-fat diet (HFD) for 5 weeks. All HFD-fed rats were then injected with streptozotocin (STZ). One week later, HFD rats injected with STZ were randomly treated with either G-CSF (200 μg/kg/day; diabetes mellitus (DM)/G-CSF) or saline (DM/saline) for 5 consecutive days. Four weeks later, serum biochemical and histology analyses were conducted. The expression of autophagy-associated proteins was determined by Western blotting. The mRNA expression of β-oxidation-related genes was determined by quantitative real-time polymerase chain reaction. HepG2 cells were cultured under high glucose (HG) conditions with G-CSF treatment, followed by Oil Red O staining for quantification of lipids. Results. Histological analysis showed lower lipid accumulation in the DM/G-CSF group than in the DM/saline-treated rats. Protein levels of LC3 and beclin-1 were higher, and those of p62 were lower in the DM/G-CSF rats than in the DM/saline-treated rats. The mRNA expression of β-oxidation-related genes was higher in DM/G-CSF rats than in the DM/saline-treated rats. Quantification of lipid levels in HepG2 cells cultured with HG and G-CSF treatment revealed no significant differences. Conclusions. Our data suggested that G-CSF potentially improves hepatic steatosis and autophagy in the liver of diabetic rats.

1. Introduction

Nonalcoholic hepatic steatosis is an initial stage of nonalcoholic fatty liver disease (NAFLD) and is defined as the accumulation of triglycerides (TG) without significant alcohol consumption in the liver [1]. Severe NAFLD can develop and is characterized by nonalcoholic steatohepatitis with increased fibrosis, and it may eventually lead to cirrhosis when combined with other metabolic syndromes [2]. Nonalcoholic hepatic steatosis is an aspect of the metabolic syndrome [3], and it is commonly associated with obesity, insulin resistance, hyperlipidemia, and diabetes [4]. Its worldwide prevalence continues to increase with the growing obesity epidemic and affects approximately 20–40% of adults in developed countries [5].

Autophagy is a process of lysosomal degradation that can degrade intracellular organelles. It can remove damaged cellular components to maintain the homeostasis of cellular energy [6]. Previous evidence has demonstrated that autophagy has a protective function that allows degradation of lipid droplets, while impaired autophagy could contribute to hepatic lipid accumulation [7]. Importantly, recent studies
have shown that activation of hepatic autophagy improves nonalcoholic hepatic steatosis as well as alcohol-related liver disease [8].

The granulocyte colony stimulating factor (G-CSF) is a regulator of neutrophil development and formation that is widely used to mobilize bone marrow-derived stem cells in the peripheral blood [9]. G-CSF also improves various liver diseases, including acute liver failure [10], steatohepatitis [11], and liver cirrhosis [12]. Previously, we revealed both the therapeutic and preventive effects of G-CSF on nonalcoholic hepatic steatosis [13, 14]. Although we identified that these effects of G-CSF are related to the reduction in the expression of lipogenesis-related genes and increase in the expression of β-oxidation-related genes, the detailed mechanisms underlying the therapeutic effects of G-CSF on hepatic steatosis remain unclear.

In this study, we explored whether the mechanisms of the therapeutic effect of G-CSF were associated with autophagy in a rat model of diabetes. In addition, to identify whether the effect of G-CSF was direct, we investigated the lipid accumulation in HepG2 cells treated with G-CSF.

2. Materials and Methods

2.1. Animals. This study was performed in accordance with the ARRIVE guidelines on animal research [15]. The Hanyang University Institutional Animal Care and Use Committee approved all experiments. We used 6-week-old male Sprague–Dawley rats (Koatech, Kyungki-do, South Korea). The rats were kept under specific pathogen-free conditions at Hanyang University Medical School Animal Experiment Center and housed in cages under conditions of controlled temperature (23 ± 2°C) and humidity (55 ± 5%) with a 12-hour artificial light and dark cycle.

2.2. Animal Model and Experimental Design. The experimental design is shown schematically in Figure 1. Starting at 7 weeks of age, all rats were randomly divided into groups and were given free access to either a standard rodent diet (normal control; n = 8) with 5.4% fat content or a high-fat diet (HFD; n = 16) with 60% fat content for 6 weeks. After 5 weeks of feeding, all the rats fed with the HFD were injected intraperitoneally with low-dose streptozotocin (STZ; 30 mg/kg). One week later, HFD rats received treatment with either intraperitoneal G-CSF (n = 8; 200 μg/kg/day) or saline (n = 8; the same volume as G-CSF) for 5 consecutive days and were fed the standard diet until the end of experiment. Four weeks after the start of treatment, all rats were sacrificed for analysis.

2.3. Serum Biochemical Analysis. Blood samples were collected from the tail vein after 8 hours of fasting, and serum was obtained by centrifugation and stored at −70°C. The levels of serum glucose, total cholesterol (TC), TG, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and free-fatty acids (FFAs) were measured by using a model AU400 auto analyzer (Olympus GmbH, Hamburg, Germany) [16]. Insulin resistance (IR) was defined as a homeostasis model assessment of insulin resistance (HOMA-IR) as insulin (μU/mL) x fasting glucose (mmol/L)/22.5 [17].

2.4. Histological Analysis. To examine the liver morphology, liver tissues were fixed in 10% formalin solution, embedded in paraffin, and then cut into 3 μm-thick sections for hematoxylin and eosin (H&E) staining. To evaluate the lipid accumulation, frozen 4 μm-thick sections of liver tissues were stained with Oil Red O as previously described [14]. Five fields were randomly selected from the individual slide. The Oil Red O-stained area was analyzed using Image-Pro Plus software (Media Cybernetics, Silver Spring, MD, USA), by calculating the percentage of the ratio of the Oil Red O-positive area to the total tissue area. All histological data were estimated by an independent blinded researcher.

2.5. Quantitative Real-Time PCR (q-PCR). Total RNA was isolated from the liver tissue using QIAzol reagent (Qiagen, Valencia, CA, USA) following the manufacturer’s instructions. The RNA (3 μg) was reverse-transcribed with reverse transcriptase (Invitrogen Co., Carlsbad, CA, USA). The mRNA expression levels were quantified using a Light Cycler® 480 System (Roche, Basel, Switzerland) with a FastStart DNA Master SYBR Green I kit (Roche). The genes of interest included those for AMP-activated protein kinase (AMPK-)α1, AMPK-α2, carnitine palmitoyltransferase (CPT1), and peroxisome proliferator-activated receptor gamma coactivator- (PGC-)α. The primers used are shown in Table 1. The crossing point of each sample was automatically calculated by the Light Cycler® program. q-PCR analysis for all samples was performed in duplicate. The transcript levels for each gene were determined by
2.6. Western Blotting. Protein samples were obtained from the liver tissue and homogenized on ice in protein lysis buffer (Pro-prep; INTRON, Seongnam, South Korea) with a protease inhibitor (Xpert protease inhibitor cocktail solution, GenDEPOT, Barker, TX, USA). Forty micrograms of proteins were resolved by 10% SDS-PAGE and transferred onto a polyvinylidene fluoride membrane (Bio-Rad, Hercules, CA, USA). After blocking with 5% bovine serum albumin, the membrane was incubated overnight at 4°C with primary antibodies against LC3, beclin-1, p62, and GAPDH (Cell Signaling Technology, Boston, MA, USA). GAPDH was used as a protein loading control. Protein bands were visualized and quantified using an Image lab 5.0 image analyzer (Bio-Rad).

2.7. Cell Culture and Treatment. HepG2 cells were obtained from the American Type Culture Collection (Manassas, VA, USA) and cultured in DMEM (Life Technologies, New York, USA) with normal glucose (5.5 mM) containing 10% FBS (Life Technologies) and 1% streptomycin/penicillin (Life Technologies). Cells were incubated at 37°C in a humidified atmosphere under 5% CO2 condition. A cell model for accumulation of intracellular lipids was created by exposure to a high glucose (HG; 45 mM) for 36 hours. For pharmacological studies, HepG2 cells were incubated with either normal glucose (5.5 mM) or HG (45 mM) medium supplemented with indicated concentrations of G-CSF (1, 10, and 100 ng/mL).

2.8. Cell Viability. HepG2 cells were cultured overnight, and then incubated with increasing concentrations (1, 10, 100, and 1000 ng/mL) of G-CSF for 36 hours. Subsequently, cells were treated with methy1thiazolylidiphenyl-tetrazolium bromide (MTT) solution (0.5 mg/mL) diluted in the medium and incubated for an additional another 2 hours. The culture medium was removed and the intracellular formazan product was dissolved in dimethylsulfoxide (DMSO). The absorbance was measured at a wavelength of 595 nm using an iMark™ Microplate Absorbance Reader (Bio-Rad). MTT assays were performed in triplicate.

2.9. Quantification of Lipids by Oil-Red O Staining. To prepare Oil Red O solution, 0.35 g Oil Red O (Sigma-Aldrich, St. Louis, MO, USA) per 100 mL of 100% isopropanol was mixed to yield an isopropanol concentration of 60%; this solution was then filtered. Briefly, the HepG2 cells were washed with PBS, followed by fixation with 10% formalin for 30 minutes. After washing with distilled water, fixed cells were washed with 60% isopropanol shortly and then stained with Oil Red O solution for 30 minutes at room temperature. Subsequently, after washing with distilled water, the Oil Red O was eluted with 100% isopropanol for 15 minutes at room temperature, and it is quantified by measuring the absorbance at a wavelength of 490 nm using an iMark™ Microplate Absorbance Reader (Bio-Rad).

2.10. Statistical Analysis. All statistical analyses were conducted using SPSS 21.0 for Windows (IBM, Armonk, NY, USA). The results are presented as the means ± standard deviations, except for the results of the histological analyses, which are presented as the means ± standard errors of the means. Comparisons of parameters among groups were performed using one-way analysis of variance (ANOVA) followed by a post hoc Tukey’s test. P values <0.05 were considered statistically significant.

3. Results

3.1. Body Weight and Serum Biochemical Analysis. The body weights of the rats from each group were not significantly different (Figure 2). At the end of the experiment, circulating glucose levels were significantly higher in the HFD-fed rats injected with STZ than in the rats form the normal control group but were similar between the DM/G-CSF and DM/saline groups (ANOVA: F(2,9) = 15.682, P < 0.05). HOMA-IR was significantly lower in the DM/G-CSF group than in the DM/saline group and did not differ between the normal control group and the DM/G-CSF group (ANOVA: F(2,9) = 13.494, P < 0.05). Finally, levels of circulating TG, AST, ALT, and FFAs were similar for all groups. TC levels

Table 1: Primer sequences used in this study.

| Primer     | Sequence                        | Size (bp) |
|------------|---------------------------------|-----------|
| AMPK-1α    | F: 5'-CAA-AGA-TTT-CTT-GTT-GGC-AAC-AAG-C-3' | 95        |
|            | R: 5'-CAA-CCA-AGT-GTA-GAC-TTC-TGAG-G-3'  |           |
| AMPK-2α    | F: 5'-CGT-GCT-GTG-AAA-CTT-ACA-CTC-T-3'  | 95        |
|            | R: 5'-GTC-ACC-TGG-GAA-TGT-CCT-GAG-TG-3' |           |
| CPT1       | F: 5'-GCT-TAT-CTT-CTA-ATG-CAC-AGC-3'    | 99        |
|            | R: 5'-CCA-TTA-CTT-GAT-ATG-TCG-3'      |           |
| PGC-1α     | F: 5'-CCT-GAA-GCT-GTT-CTG-ACA-AGC-3'   | 85        |
|            | R: 5'-ATT-GGT-GAC-ACC-ACC-GGT-3'      |           |
| GAPDH      | F: 5'-CCT-TCT-CTT-GTT-GAG-AAG-GTG-3'   | 96        |
|            | R: 5'-CGT-GGG-TAG-AGT-CAT-GAG-GA-3'   |           |

AMPK-1α, AMP-activated protein kinase-1α; AMPK-2α, AMP-activated protein kinase-2α; CPT1, carnitine palmitoyltransferase 1; PGC-1α, peroxisome proliferator-activated receptor gamma coactivator-1α; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; F, forward; and R, reverse.
were significantly higher in the DM/saline group than in the normal control group (Table 2).

3.2. Hepatic Lipid Accumulation. The progression of hepatic steatosis was verified by H&E and Oil Red O staining. At the end of the experiment, the liver tissues from the DM/saline group showed severe micro- and macrovesicular steatosis and numerous ballooning hepatocytes. In contrast, the liver tissues from the DM/G-CSF group exhibited no fat accumulation; this was not different from the case for the liver tissues from the normal control group (Figure 3(a)). The accumulation of lipid droplets as indicated by Oil Red O staining was significantly lower in the DM/G-CSF group than in the DM/saline group and was significantly different between the DM/G-CSF group and normal control group (Figures 3(b) and 3(c)) (ANOVA: F_{(2,82)} = 79.387, P < 0.05).

3.3. Expression of Proteins Related to Autophagy. To confirm whether the ameliorative effects of G-CSF on hepatic steatosis were associated with autophagy, we examined the protein expression of autophagy markers, including LC3, beclin-1, and p62 by Western blotting. The protein level of the LC3, as determined by calculating the LC3 conversion (LC3-II/LC3-I), was significantly higher in the DM/G-CSF group than in the DM/saline group and the normal control group (Figure 4(a)) (ANOVA: F_{(2,8)} = 15.552, P < 0.05). The protein level of beclin-1 was significantly higher in the DM/G-CSF group than in the DM/saline group and the normal control group (Figure 4(b)) (ANOVA: F_{(2,7)} = 16.446, P < 0.05). The protein level of p62 was significantly lower in the DM/G-CSF group than in the DM/saline group, and it was not significantly different from that in the normal control group (Figure 4(c)) (ANOVA: F_{(2,10)} = 16.457, P < 0.05).

3.4. Expression of mRNAs Related to β-oxidation. To investigate the alteration of the expression of β-oxidation-related genes by G-CSF, mRNA levels of β-oxidation-related genes, including AMPK-1α, AMPK-2α, CPT1, and PGC-1α, in the liver were examined by q-PCR. The mRNA level of AMPK-1α was significantly higher in the DM/G-CSF group than in the DM/saline group and the normal control group (Figure 5(a)) (ANOVA: F_{(2,15)} = 8.615, P < 0.05). The mRNA level of AMPK-2α was significantly higher in the DM/G-CSF group than in the DM/saline group and the normal control group; there was a significant difference between the mRNA level of AMPK-2α in the DM/G-CSF group and the normal control group (Figure 5(b)) (ANOVA: F_{(2,14)} = 20.619, P < 0.05). The mRNA level of CPT1 was significantly higher in the DM/G-CSF group than in the DM/saline group and the normal control group (Figure 5(c)) (ANOVA: F_{(2,13)} = 17.477, P < 0.05). The mRNA level of PGC-1α was significantly higher in the DM/G-CSF group than in the DM/saline group and the normal control group (Figure 5(d)) (ANOVA: F_{(2,11)} = 11.673, P < 0.05).

3.5. Effect of G-CSF on Lipid Accumulation in HepG2 Cells. Various concentrations of G-CSF (1, 10, 100, and 1000 ng/mL) were added to the culture medium of HepG2 cells. After 36 hours, cell viability was measured using the MTT assay. Treatment with G-CSF at concentrations up to 100 ng/mL had no cytotoxic effects on HepG2 cells. However, treatment with G-CSF at a concentration of 1000 ng/mL reduced cell viability, as observed by comparisons with the untreated group (Figure 6(a)). To determine whether G-CSF is directly involved in HG-induced lipid accumulation, HepG2 cells were treated with noncytotoxic concentrations of G-CSF (1, 10, and 100 ng/mL) in the presence of HG conditions for 36 hours, and lipid accumulation was quantified by Oil Red O staining. Intracellular lipid accumulation was significantly higher in the HepG2 cells exposed to HG conditions than in the HepG2 cells exposed to normal glucose conditions. However, cotreatment with HG and increasing amounts of G-CSF (1, 10, and 100 ng/mL) had no effect on lipid accumulation in the HepG2 cells (Figure 6(b)).
4. Discussion

In the present study, we examined the effects of G-CSF treatment on hepatic steatosis in a rat model. We demonstrated that G-CSF treatment emeliorated β-oxidation as well as hepatic steatosis in the liver tissue. Moreover, G-CSF induced autophagy activation, which provides a molecular explanation for the therapeutic effects of G-CSF on hepatic steatosis. We also confirmed that G-CSF did not affect the lipid accumulation in the HepG2 liver cancer cells, which indicates that G-CSF may not have a direct beneficial effect on hepatic steatosis by signaling through the G-CSF receptor.

Growing evidence has demonstrated the contribution of autophagy in the regulation of lipid metabolism. There have been studies that activation of autophagy could reduce the number of lipid droplets resulting in therapeutic effects against NAFLD [18], while defective autophagy might trigger the accumulation of lipids leading to the development of NAFLD [19]. In the present study, autophagy was activated in the liver of rats treated with G-CSF, with higher levels of beclin-1 protein and LC3-II/LC3-I (LC3
Figure 4: Expression of proteins related to autophagy in the liver. The levels of microtubule-associated protein light chain 3 (LC3) (a), beclin-1 (b), and p62 (c) proteins in the liver tissues were measured by Western blotting. The representative images of the Western blotting analyses are displayed on the upper panels, and quantitative densitometry analysis is shown in the lower panels. LC3 expression was normalized by calculating LC3 conversion as the ratio of LC3-II/LC3-I expression. Beclin-1 and p62 expression levels were normalized by comparison with the levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). M, marker and DM, diabetes mellitus. All data are expressed as the means ± standard deviations (n = 8 per group). *P < 0.05 vs. normal control. †P < 0.05 vs. DM/saline.

Figure 5: mRNA expression levels of β-oxidation-related genes in the rat liver. mRNA expression of AMP-activated protein kinase (AMPK)-1α (a), AMPK-2α (b), carnitine palmitoyltransferase (CPT)1 (c), and the peroxisome proliferator-activated receptor gamma coactivator (PGC)-1α (d) was measured by quantitative real-time polymerase chain reaction (q-PCR) in duplicate. The transcript levels were normalized by comparison with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression. DM, diabetes mellitus. All data are expressed as the means ± standard deviations (n = 8 per group). *P < 0.05 vs. normal control. †P < 0.05 vs. DM/saline.
conversion), and lower levels of expression of p62 protein in rats treated with G-CSF. Beclin-1 is a major indicator of the autophagic activity; it forms a kinase complex with class III phosphatidylinositol 3-kinase [20]. LC3 is a representative marker of the activation of autophagy. It is located specifically on the outer membrane of autophagosomes, which forms the phagophore and induces lysosomal degradation [21]. The expression of LC3 could be reported as LC3 conversion because LC3-I is conjugated to phosphatidylethanolamine to form LC3-II, which is essential for the formation of the autophagosome when autophagy is initiated [22]. P62 links LC3 and ubiquitylated substrates for delivery to the autophagosome, which is efficiently degraded by lysosomal acid hydrolases during the normal autophagic activity [23]. Thus, it has been suggested that increased p62 levels relate to suppressed autophagy, and decreased p62 levels relate to autophagy activation [24]. A recent study revealed that autophagy activation following treatment with a polyphenol fraction could prevent nonalcoholic hepatic steatosis by upregulation of autophagy markers, such as beclin-1, and LC3 conversion with decreased p62 levels in the liver tissue of rats fed a cafeteria diet [25]. Therefore, with regard to the results of our study, G-CSF treatment may decrease lipid droplet formation by enhancing autophagy, which may be considered a beneficial effect of G-CSF treatment on hepatic steatosis.

Autophagy contributes to the generation of fatty acids by breaking down lipid droplets and formation of the autolysosome, which is an autophagosome combined with a lysosome [7, 26]. The fatty acids generated from the lipid droplets by autophagy are consumed by mitochondrial \( \beta \)-oxidation, a process that is critical for the disposal of fatty acids [27, 28]. \( \beta \)-oxidation has an important role on the \( \beta \)-oxidation genes, such as AMPK-1\( \alpha \), AMPK-2\( \alpha \), CPT1, and PGC-1\( \alpha \), accompanied with the enhancement of autophagy in the rat liver. Further studies are needed to determine whether increased \( \beta \)-oxidation is dependent on G-CSF-induced autophagy, and whether protein expression levels of these genes are similar to the corresponding mRNA expression.

NAFLD is a common chronic liver disease and is closely associated with type 2 diabetes mellitus (T2DM) [32]. NAFLD and T2DM are components of metabolic syndrome and share a number of related clinical features such as IR, dyslipidemia, and visceral obesity [33]. NAFLD has an estimated prevalence of approximately 70% in patients with T2DM [34]. In our study, a rat model of NAFLD was developed using HFD feeding and low-dose STZ injection. The model mimicked the metabolic characteristics and a natural history of T2DM in humans [35]. We identified hepatic steatosis via the histological evaluation of the liver tissues from our rat model, indicating that these rats with T2DM also had NAFLD. In addition, we showed that G-CSF treatment reduced hepatic steatosis in the rats, suggesting the potential of G-CSF for the treatment of hepatic steatosis in T2DM.

Previous studies have suggested several potential mechanisms underlying the therapeutic effect of G-CSF on various liver diseases, including the induction of bone marrow-derived cell mobilization and direct effects of the G-CSF receptor-mediated signaling pathway [12, 36]. Our previous study also confirmed the presence of the G-CSF receptor in the rat liver tissue [14]. However, G-CSF
treatment had no effect on lipid accumulation in HepG2 cells. Taken together, our data support the idea that the therapeutic effects of G-CSF might be associated with the induction of bone marrow-derived cell mobilization by G-CSF rather than a direct effect resulting from G-CSF receptor activation in the liver.

This study has several limitations. First, we were unable to investigate the therapeutic mechanisms underlying the action of G-CSF on hepatic steatosis, in association with its effects on bone marrow-derived mobilization by G-CSF. This will require further investigations of the bone marrow-dependent effects of G-CSF. Second, treatment regimens including dosage, timing, and duration of G-CSF need to be established. Finally, our study did not analyze the expression levels of other autophagy markers or histological evidence related to autophagy. Additional studies are needed to more precisely evaluate the mechanisms involved in autophagy.

In conclusion, our study showed that G-CSF improved hepatic steatosis and induced the activation of β-oxidation and autophagy in a rat model. We speculate that the activation of autophagy by G-CSF could be associated with the reduction in hepatic steatosis through the upregulation of β-oxidation-related genes. In addition, we found that G-CSF did not reduce intracellular lipid accumulation, which implies that the therapeutic effect of G-CSF may be related to bone marrow mobilization.

**Data Availability**

The data used to support the findings of this study are available from the corresponding author upon request.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**Authors’ Contributions**

Hyun-Woo Joo and Yi-Sun Song contributed equally to this work.

**Acknowledgments**

The authors with to thank Hanyang University.

**References**

[1] C. P. Day and O. F. W. James, "Hepatic steatosis: innocent bystander or guilty party?" Hepatology, vol. 27, no. 6, pp. 1463–1466, 1998.

[2] R. S. Rector, J. P. Thyfault, Y. Wei, and J. A. Ibdah, "Non-alcoholic fatty liver disease and the metabolic syndrome: an update," World Journal of Gastroenterology, vol. 14, no. 2, pp. 185–192, 2008.

[3] P. Marceau, S. Biron, F.-S. Hould et al., "Liver pathology and the metabolic syndrome X in severe obesity," The Journal of Clinical Endocrinology & Metabolism, vol. 84, no. 5, pp. 1513–1517, 1999.

[4] J. D. Marceau, L. S. Szczepaniak, R. Dobbins et al., "Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity," Hepatology, vol. 40, no. 6, pp. 1387–1395, 2004.

[5] G. Nuremberg, A. Baranova, and Z. M. Younossi, "Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults," Alimentary Pharmacology & Therapeutics, vol. 34, no. 3, pp. 274–285, 2011.

[6] M. J. Czaja, "Functions of autophagy in hepatic and pancreatic physiology and disease," Gastroenterology, vol. 140, no. 7, pp. 1895–1908, 2011.

[7] R. Singh, S. Kaushik, Y. Wang et al., "Autophagy regulates lipid metabolism," Nature, vol. 458, no. 7242, pp. 1131–1135, 2009.

[8] V. J. Xiang and P. Gual, “Autophagy and non-alcoholic fatty liver disease,” BioMed Research International, vol. 2014, Article ID 120179, 13 pages, 2014.

[9] A. D. Panopoulos and S. S. Watowich, "Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and "emergency" hematopoiesis," Cytokine, vol. 42, no. 3, pp. 277–288, 2008.

[10] N. Rolando, M. Clapperton, J. Wade, G. Panetsos, G. Mufti, and R. Williams, "Granulocyte colony-stimulating factor improves function of neutrophils from patients with acute liver failure," European Journal of Gastroenterology & Hepatology, vol. 12, no. 10, pp. 1135–1140, 2000.

[11] L. Panetsos, J.-F. Lambert, L. Rubbia-Brandt et al., "Granulocyte-colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial," Hepatology, vol. 48, no. 1, pp. 221–229, 2008.

[12] S. Chalandon, A. Smedile, P. Omedè et al., "Feasibility and safety of G-CSF administration to induce bone marrow-derived cells mobilization in patients with end stage liver disease," Journal of Hepatology, vol. 45, no. 1, pp. 13–19, 2006.

[13] Y.-S. Olivero, C.-H. Fang, B.-I. So, J.-Y. Park, D. W. Jun, and K.-S. Kim, "Therapeutic effects of granulocyte-colony stimulating factor on non-alcoholic hepatic steatosis in the rat," Annals of Hepatology, vol. 12, no. 1, pp. 115–122, 2013.

[14] Y.-S. Park, H.-W. Joo, I.-H. Park et al., "Granulocyte-colony stimulating factor prevents the development of hepatic steatosis in rats," Annals of Hepatology, vol. 14, no. 2, pp. 243–250, 2015.

[15] C. Shen, W. J. Browne, I. Cuthi, M. Emerson, and D. G. Altman, "Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research," Veterinary Clinical Pathology, vol. 41, no. 1, pp. 27–31, 2012.

[16] Y.-M. Fan, O. Raitakari, M. Kähönen et al., "Hepatic lipase promoter C-480T polymorphism is associated with serum lipids levels, but not subclinical atherosclerosis: the cardiovascular risk in Young Finns study," Clinical Genetics, vol. 76, no. 1, pp. 46–53, 2009.

[17] D. R. Nutri-Kähönen, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, and R. C. Turner, "Homeostasis model assessment: insulin resistance and 2-cell function from fasting plasma glucose and insulin concentrations in man," Diabetologia, vol. 28, no. 7, pp. 412–419, 1985.

[18] C.-W. Naylor, H. Zhang, M. Li et al., "Pharmacological promotion of autophagy alleviates steatosis and injury in alcoholic and non-alcoholic fatty liver conditions in mice," Journal of Hepatology, vol. 58, no. 5, pp. 993–999, 2013.

[19] A. González-Rodríguez, R. Mayoral, N. Agra et al., "Impaired autophagic flux is associated with increased endoplasmic reticulum stress during the development of NAFLD," Cell Death & Disease, vol. 5, no. 4, Article ID e1179, 2014.
[20] R. Valdecantos, H. J. Zeh, M. T. Lotze, and D. Tang, “The beclin 1 network regulates autophagy and apoptosis,” Cell Death & Differentiation, vol. 18, no. 4, pp. 571–580, 2011.
[21] Q. Zhang, Y. Li, T. Liang et al., “ER stress and autophagy dysfunction contribute to fatty liver in diabetic mice,” International Journal of Biological Sciences, vol. 11, no. 5, pp. 559–568, 2015.
[22] S. J. Lu III, S. M. Kulich, G. Uechi et al., “Regulation of the autophagy protein LC3 by phosphorylation,” The Journal of Cell Biology, vol. 190, no. 4, pp. 533–539, 2010.
[23] M. Balasubramani and Y. Ichimura, “Physiological significance of selective degradation of p62 by autophagy,” FEBS Letters, vol. 584, no. 7, pp. 1374–1378, 2010.
[24] N. Mizushima and T. Yoshimori, “How to interpret LC3 immunoblotting,” Autophagy, vol. 3, no. 6, pp. 542–545, 2007.
[25] M. Parafati, A. Lascala, V. M. Morittu et al., “Bergamot polyphenol fraction prevents nonalcoholic fatty liver disease via stimulation of lipophagy in cafeteria diet-induced rat model of metabolic syndrome,” The Journal of Nutritional Biochemistry, vol. 26, no. 9, pp. 938–948, 2015.
[26] J. Trimболи and A. M. Cuervo, “Regulation of liver metabolism by autophagy,” Gastroenterology, vol. 150, no. 2, pp. 328–339, 2016.
[27] Y. Wei, R. S. Rector, J. P. Thiyfault, and J. A. Ibdah, “Nonalcoholic fatty liver disease and mitochondrial dysfunction,” World Journal of Gastroenterology, vol. 14, no. 2, pp. 193–199, 2008.
[28] Y. Kawano and D. E. Cohen, “Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease,” Journal of Gastroenterology, vol. 48, no. 4, pp. 434–441, 2013.
[29] J. K. Reddy and M. Sambasiva Rao, “Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 290, no. 5, pp. G852–G858, 2006.
[30] H. Cichoz-Lach and A. Michalak, “Oxidative stress as a crucial factor in liver diseases,” World Journal of Gastroenterology, vol. 20, no. 25, pp. 8082–8091, 2014.
[31] W.-X. Ding, “Drinking coffee burns hepatic fat by inducing lipophagy coupled with mitochondrial β-oxidation,” Hepatology, vol. 59, no. 4, pp. 1235–1238, 2014.
[32] A. N. Mavrogiannaki and I. N. Migdalis, “Nonalcoholic fatty liver disease, diabetes mellitus and cardiovascular disease: newer data,” International Journal of Endocrinology, vol. 2013, Article ID 450639, 8 pages, 2013.
[33] G. C. Farrell, “The liver and the waistline: fifty years of growth,” Journal of Gastroenterology and Hepatology, vol. 24, no. 3, pp. S105–S118, 2009.
[34] A. Lonardo, S. Ballestri, G. Guaraldi et al., “Fatty liver is associated with an increased risk of diabetes and cardiovascular disease—evidence from three different disease models: NAFLD, HCV and HIV,” World Journal of Gastroenterology, vol. 22, no. 44, pp. 9674–9693, 2016.
[35] H. Nascimbeni, F. Cui, J. J. Dong et al., “Therapeutic effects of globular adiponectin in diabetic rats with nonalcoholic fatty liver disease,” World Journal of Gastroenterology, vol. 20, no. 40, pp. 14950–14957, 2014.
[36] Y. Ji, U. Dahmen, N. Madrahimov, F. Madrahimova, W. Xing, and O.Dirsч, “G-CSF administration in a small-for-size liver model,” Journal of Investigative Surgery, vol. 22, no. 3, pp. 167–177, 2009.